Stevanato Group S.p.A. (FRA:87N)

Market Cap	3.58B -39.1%
Revenue (ttm)	1.17B +7.0%
Net Income	140.60M +22.6%
EPS	0.51 +19.6%
Shares Out	n/a
PE Ratio	25.46
Forward PE	22.31
Dividend	0.05 (0.41%)
Ex-Dividend Date	Jun 5, 2025

Volume	n/a
Average Volume	25
Open	14.00
Previous Close	14.00
Day's Range	13.30 - 14.10
52-Week Range	13.30 - 23.60
Beta	n/a
RSI	19.07
Earnings Date	Mar 5, 2026

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injector...

• Industry: Commercial Physical and Biological Research
• Founded: 1949
• Employees: 5,521
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 87N

Financial Performance

In 2024, Stevanato Group's revenue was 1.10 billion, an increase of 1.72% compared to the previous year's 1.09 billion. Earnings were 117.78 million, a decrease of -19.13%.